PD35: Prostate Cancer: Advanced (including Drug Therapy) II

Podium Session Moderator(s)

• 

  Sam Chang, MD,MBA (he/him/his)

  Patricia & Rodes Hart Chair of Urologic Surgery, Chief Surgical Officer
  Vanderbilt University Medical Center
• SF

  Stephen Freedland, MD

  Cedars-Sinai Medical Center
• 

  Judd Moul, MD, FACS

  James H Semans MD Professor of Surgery
  Duke University

Presentations:

• 7:00 AM – 7:10 AM

  PD35-01: Which Patients With cN1 Disease At PET/CT Are Affected By Systemic Disease? Implications For Tailored Treatment Approaches Based On A Large Multi-Institutional Series
  

  Podium Presenter: Elio Mazzone
• 7:10 AM – 7:20 AM

  PD35-02: When Is Neoadjuvant Androgen Deprivation Therapy Beneficial for Highly Aggressive Prostate Cancer Candidates to Radical Prostatectomy? Implications for Multi-modal Tailored Approaches and Trials Design
  

  Podium Presenter: Francesco Maria Barletta, MD – IRCCS Ospedale San Raffaele
• 7:20 AM – 7:30 AM

  PD35-03: The significance of De-Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy
  

  Podium Presenter: Fahad Quhal, MD – King fahad specialist hospital in Dammam
• 7:30 AM – 7:40 AM

  PD35-04: Quantitative Piflufolastat F18 (PSMA) Scan Indices as a Response Imaging-Biomarker to Androgen Deprivation Therapy in Veterans with Newly Diagnosed Metastatic Prostate Cancer.
  

  Podium Presenter: Nicholas George Nickols, MD – UCLA David Geffen School of Medicine
• 7:40 AM – 7:50 AM

  PD35-05: Initial experience of [¹⁷⁷Lu]Ludotadipep treatment in patients with [¹⁸F]PSMA PET CT positive metastatic castration-resistant prostate cancer: preliminary study
  

  Podium Presenter: Dong Ho Shin, MD – Seoul St. Mary's Hospital
• 7:50 AM – 8:00 AM

  PD35-06: Health-related quality of life in low-income men after surgical castration for metastatic prostate cancer
  

  Podium Presenter: Thomas Gaither
• 8:00 AM – 8:10 AM

  PD35-07: Analysis of Discontinuation Rates and Causes of Early Discontinuation of Novel Oral Hormone Therapy in Men with Advanced Prostate Cancer
  

  Podium Presenter: David Gangwish
• 8:10 AM – 8:20 AM

  PD35-08: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies
  

  Podium Presenter: Neal D. Shore, MD
• 8:20 AM – 8:30 AM

  PD35-09: Homologous recombination deficiency (HRD) score in Chinese aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate
  

  Podium Presenter: Sha Zhu – Netherlands Cancer Institute
• 8:30 AM – 8:40 AM

  PD35-10: Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
  

  Podium Presenter: Masaki Shiota, MD, PHD
• 8:40 AM – 8:50 AM

  PD35-11: The impact of older age on the oncological outcomes for high-risk metastatic hormone-sensitive prostate cancer treated with upfront intensive therapy
  

  Podium Presenter: Shingo Hatakeyama, MD – Hirosaki University Graduate School of Med
• 8:50 AM – 9:00 AM

  PD35-12: Association between use of second-generation antiandrogens and overall survival in patients with metastatic prostate cancer – a population-based study
  

  Podium Presenter: Isaac Elijah Kim, Jr.